DRREDDY
2 deep-dives · 32 policy notes
What has moved DRREDDY
20 dated calls from the policy coverage · 12 positive · 2 negative · 6 watch
- Watch2026-10-19inferred
The price to the stockist is preserved by the formula, so the arithmetic is margin-neutral for the manufacturer at the point of sale. What changes is the incentive for the trade to push the brand, and that is where the volume risk sits
Policy Pulse - Ministries & Regulators - 19 Oct 2026 - Positive2026-10-19inferred
The US is the largest market for all four, and a 100% secondary tariff on all Indian goods was the single largest unhedged risk in their US revenue line
Policy Pulse - Modi / India Govt - 19 Oct 2026 - Positive2026-10-16inferred
Pharmaceuticals are the largest single Indian export category to the US and the one where a tariff differential against competing suppliers is worth most per unit; the first-tranche text is the mechanism that delivers it
Policy Pulse - Ministries & Regulators - 16 Oct 2026 - Watch2026-10-15inferred
Section 113 applies to "all goods," so Indian pharmaceutical exports are formally in scope — but the provision is conditioned on new purchases, and no target list has been published
Policy Pulse - Global Spillover - 15 Oct 2026 - Positive2026-10-15inferred
Pharmaceuticals are among the most consistent export earners in the monthly basket, and a record goods-export month implies the pharma line held or improved
Policy Pulse - Ministries & Regulators - 15 Oct 2026 - Negative2026-10-13inferred
Section 113 attaches to all goods, not just energy-linked ones, so US-bound generic exporters carry headline risk on top of the existing tariff stack
Policy Pulse - Global Spillover - 13 Oct 2026 - Watch2026-10-13inferred
The October 14 DGHS deadline for the anti-cancer drug positive list carries a proposed 30% trade-margin cap, which is a price intervention into the oncology channel rather than a volume change
Policy Pulse - Ministries & Regulators - 13 Oct 2026 - Positive2026-10-13inferred
The PM explicitly cited India's 20% share of global generics as strategic weight rather than as an export statistic
Policy Pulse - Modi / India Govt - 13 Oct 2026 - Watch2026-10-09
Manufacturer selling prices are untouched, so the direct earnings impact is minimal; the reputational and volume effect on cancer portfolios is the only channel
Policy Pulse - Ministries & Regulators - 09 Oct 2026 - Positive2026-10-08inferred
Automated refunds, wider ITC on input services and capital goods, and a ₹10,000 floor on demand notices directly cut working capital locked in the tax system for large manufacturers
Policy Pulse - Ministries & Regulators - 08 Oct 2026 - Positive2026-10-07
Exporters and inverted-duty claimants are the direct beneficiaries of a 17-day refund clock and 90% automated release — a working-capital release, not a tax cut
Policy Pulse - Ministries & Regulators - 07 Oct 2026 - Positive2026-10-07
Pharma is a named market-access category; EFTA tariff elimination lowers the cost of Swiss/EU intermediates
Policy Pulse - Modi / India Govt - 07 Oct 2026 - Positive2026-10-06
Exporters are the largest cohort of GST refund claimants; 90% automatic release is a direct working-capital release
Policy Pulse - Ministries & Regulators - 06 Oct 2026 - Negative2026-10-05
The tariff applies to all goods from a designated country. Indian pharma, textiles and engineering exports into the US would be the largest collateral exposure, and no sector carve-out has been published
Policy Pulse - Global - 05 Oct 2026 - Positive2026-10-05
The 90%-automatic refund mechanism is targeted squarely at exporters, whose working capital is the binding constraint on an export-heavy P&L. Pharma is the largest single GST-refund claimant category
Policy Pulse - Ministries & Regulators - 05 Oct 2026 - Positive2026-10-05
Pharma is one of four export categories the Prime Minister named for Swiss market access, and life sciences is one of six named investment targets. Switzerland is a branded-pharma market where Indian generic filings have a long approval runway
Policy Pulse - Modi / India Govt - 05 Oct 2026 - Watch2026-10-01inferred
Indian pharma retains the Section 232 generic exemption negotiated earlier, but remains inside the Section 301 overcapacity universe. A new duty tier on Indian manufacturing would hit the generic export book ⚠️ inferred from the investigation's scope, not from any named company
Policy Pulse - Global Spillover - 01 Oct 2026 - Watch2026-10-01
Large-cap and mid-cap pharma is not the target of the scheme — these names largely exceed the MSME eligibility test, so the read-through is thematic rather than financial. Separately, this complex remains exposed to the pending Section 301 overcapacity investigation covering 16 economies including India and to the September 29 expansion of Section 232 medical-device tariffs. Neither is a PRIP effect ⚠️ sector-only, weak stock inference
Policy Pulse - Ministries & Regulators - 01 Oct 2026 - Positive2026-09-30
Top Nifty 50 gainer on September 29 at +2.53%; the specialty portfolio and the US generics base both sit comfortably outside the 100% tariff line
Policy Pulse - Global Spillover - 30 Sep 2026 - Positive2026-09-30inferred
Export earners are the natural hedge if the rupee's support shifts from policy-induced inflows to a shrinking forward book ⚠️ inferred
Policy Pulse - Ministries & Regulators - 30 Sep 2026
Deep-dive research
Policy Pulse — Global Spillover — 07 Jul 2026
USTR Section 301 forced-labor tariff hearings begin Jul 7 — 60 economies targeted. China adds 20 Japanese entities to export control list. NZ-India FTA passes first reading. Digital customs cuts electronic clearance to 6 hrs. Key: INFY, TCS, SUNPHARMA, DIXON.
Policy Pulse — Ministries — 07 Jul 2026
DAC approves ₹52,000 Cr defence procurement (BEL, HAL, BDL, PARAS). India-EU FTA legal scrubbing accelerated — textile/pharma boost (TRIDENT, WELSPUN, DRREDDY). SEBI buyback cap at 15% from Aug 1. SEZ RoDTEP extension.
Mentioned in Policy Pulse
Policy Pulse - Ministries & Regulators - 19 Oct 2026
NPPA capped trade margins on 137 cancer drugs at 30% from November 9, a margin reset that hits MEDPLUS and re-prices oncology-heavy portfolios like NATCOPHARM, while Jio's 30x anchor book keeps BSE and ANGELONE on the right side of the primary market.
Policy Pulse - Modi / India Govt - 19 Oct 2026
India's 100% tariff tail risk is gone: the Graham Act waiver removes the secondary duty that would have hit every Indian shipment, putting IOC, BPCL and HINDPETRO back on Russian crude without an export penalty, while WAAREEENER faces the one duty that was not waived.
Policy Pulse - Ministries & Regulators - 16 Oct 2026
The India-US BTA first tranche is finalised and in legal drafting, with Piyush Goyal and Nirmala Sitharaman both pushing for signature, a positive for SUNPHARMA, DRREDDY and WELSPUNLIV. The MoD signed Rs 4,106 crore of contracts led by a Rs 2,563 crore IAF satellite, and SEBI rewrote the closing auction session from December 7.
Policy Pulse - Modi / India Govt - 13 Oct 2026
PM Modi told the Bloomberg New Economy Forum on October 13 that the routes of globalisation have become chokepoints, naming supply chains, energy, critical minerals and payments, a framing that maps to TCS, INFY, SUNPHARMA and HINDCOPPER. The PMO named no company, so every mapping is inferred.
Policy Pulse - Ministries & Regulators - 09 Oct 2026
The RBI raised daily CRR maintenance to 99% and lined up Rs 25,000 crore of bond sales, negative for rate-sensitive NBFCs and bond-funded lenders; SEBI mandated a colour-coded credit risk-o-meter, positive for CRISIL and ICRA; and a 30% cap on cancer-drug trade margins lifted Apollo Hospitals and Fortis while TCS led a 3% Nifty IT rally.
Policy Pulse - Ministries & Regulators - 08 Oct 2026
The 57th GST Council left rates untouched but recommended removing GST officers' arrest powers, raising the prosecution threshold to Rs 5 crore, cutting the general penalty to Rs 10,000 and automating refunds and ITC, positive for SUNPHARMA, DRREDDY and CIPLA and for TCS and INFY on services-export facilitation; the reported deferral of the UPI merchant fee to January 2027 took 5.2 percent off PAYTM and 4.5 percent off MOBIKWIK, while TCS opened Q2 FY27 with profit up 15 percent to Rs 13,884 crore and a further Rs 12 dividend.
Policy Pulse - Ministries & Regulators - 07 Oct 2026
The RBI hiked the repo rate 25 basis points to 5.50 percent, changed its stance to calibrated tightening and revised FY27 GDP up 40 basis points to 7.1 percent, sending the Sensex down 429 points to 72,638.70 - negative for LICHSGFIN, PNBHOUSING, DLF and MARUTI but positive for HDFCBANK, ICICIBANK and SBIN on net interest margin. The 57th GST Council slipped a second time to October 8 with a proposed 17-day export refund clock, positive for SUNPHARMA, CIPLA and INFY, SEBI exempted eligible AA-minus issuers from the merchant-banker requirement on private-placement debt, positive for PFC, RECLTD and BSE, and L&T won a 5,000-10,000 crore main-plant notice to proceed for the 2x800 MW Chandrapura thermal project.
Policy Pulse - Modi / India Govt - 07 Oct 2026
PM Modi inaugurates India Mobile Congress 2026 on October 8 at Yashobhoomi and met the GSMA board, with Starlink declaring its India launch ready after building 20 gateway sites, a mixed signal for BHARTIARTL and IDEA and a positive for INDUSTOWER, TEJASNET and HFCL on densification and backhaul. Modi and Swiss President Parmelin address the second India-EFTA Prosperity Summit with the USD 100 billion TEPA investment target, the direct read-through for NESTLEIND and ABB. The Rural Development Ministry notified 375 permissible works under VB-G RAM G in a 41 percent expansion supporting PNCINFRA, HINDUNILVR and M&M.
Policy Pulse - Ministries & Regulators - 06 Oct 2026
The Ministry of Defence signed a Rs 661.50 crore BrahMos fire-control and launcher contract for Indian Navy ships at a minimum 68% indigenous content - BEL and LT are the inferred beneficiaries because PIB names no listed company. The RBI decides rates tomorrow with a 25 basis point hike to 5.50% near-fully priced, the 57th GST Council was rescheduled for a second time to October 8, and SEBI is reported to be partly reversing the Closing Auction Session for derivatives settlement, a positive for BSE, ANGELONE and MOTILALOFS. Trent's 23% Q2 revenue beat drove a 12.6% surge to a Rs 1.5 trillion market cap while Coal India and Tech Mahindra led the day's losses as the Sensex closed 685 points higher at 73,067.81.
Policy Pulse - Ministries & Regulators - 05 Oct 2026
The RBI's MPC opened a three-day meeting with roughly 60% of polled economists expecting the first repo hike since February 2023 - a 25bp move to 5.50% on October 7 that would pressure LICHSGFIN, DLF and MARUTI - while the 57th GST Council meets the same day with a pre-announced compliance, refunds and ITC package that is positive for SUNPHARMA, WELSPUNLIV and PAYTM. SEBI's Project Jagrook went live on every broker website today, and the Rs 80,000 crore Project-75(I) submarine programme with TKMS reached final approval stage as the clearest single positive for MAZDOCK.
Policy Pulse - Modi / India Govt - 05 Oct 2026
PM Modi and Swiss President Guy Parmelin signed five agreements at Hyderabad House on Monday, pairing expanded market access for Indian agriculture, pharma, textiles and engineering goods with a $100 billion EFTA investment target and fresh channels in biotech, life sciences, banking and insurance - a positive read-through for SUNPHARMA, WELSPUNLIV and NESTLEIND - alongside a Migration and Mobility Partnership and a Young Professionals Agreement. The PMO named no company, so every mapping here is inferred and confidence-marked. Forward catalyst: Chennai Metro Phase II's first 14 km on October 11.
Policy Pulse - Global Spillover - 01 Oct 2026
G20 trade ministers endorsed a Milwaukee Framework on steel overcapacity as Greer put the MFN principle itself up for review, while a Section 301 overcapacity probe covering 16 economies including India remains the unexercised risk to SUNPHARMA, WELSPUNLIV and BHARATFORG. Brent went back above $100 on China's fuel-export halt, lifting XOM and CVX against DAL and CCL, the US 10-year held near 5.28% after its biggest quarterly gain since 1994, and Micron's blowout quarter drove a 2.9-3.3% Nikkei rally.
Policy Pulse - Ministries & Regulators - 01 Oct 2026
The Finance Ministry cut the diesel and ATF export levy for a second fortnight, positive for IOC, BPCL and RELIANCE, as GST crossed Rs 2 lakh crore for a third month and the manufacturing PMI hit a seven-month high of 55.1. SEBI cleared corporate bond index futures for the NSE, the AMCA prototype RFP closed on 30 October with LT, BEL, BHARATFORG, BEML and DATAPATTNS named in the three shortlisted consortia while HAL did not qualify, and the rupee closed at 96.31 into a live RBI hike risk on October 7.
Policy Pulse - Global Spillover - 30 Sep 2026
The G20 Trade Ministerial opened in Milwaukee on steel excess capacity, MFN erosion and forced labour - the same ground as the Section 301 tariffs under challenge at the Court of International Trade - while core PCE at 3.0% cut October Fed hike odds from 71% to 35% and eased the front end. Saudi Arabia restarted the East-West pipeline and Yanbu loadings, Gulf exports recovered to 23.3 mbpd with Brent near $103, and India kept 0% Section 232 tariffs on specialty drugs, supporting SUNPHARMA and DRREDDY.
Policy Pulse - Ministries & Regulators - 30 Sep 2026
The CGA put the fiscal deficit at 41.9% of the FY27 target with five months gone, the RBI reported a record $200bn net forward dollar book as the concessional FCNR(B) window closed, and SEBI's Pandey rebuilt FPI onboarding rails while confirming no exchange interoperability and no changes outside the CAS paper. BSE replaced Wipro in the Nifty 50, the Andaman offshore mineral auction returns on October 1, and SEBI's 215th Board rewrote PMS regulations for MOTILALOFS and BSE.
Policy Pulse - Modi / India Govt - 30 Sep 2026
The Cabinet approved the Rs 1.86 lakh crore PM-DHARA scheme - 135 GW of renewable evacuation plus 50 GWh of battery storage - as part of a Rs 2.79 lakh crore package with the Rabi MSP policy and a Delhi traffic system, drawing POWERGRID, KEC, KPIL and the transformer and storage complex into focus. Modi also spoke with Trump as Goyal met Greer in Milwaukee on the interim trade deal, the Supreme Court kept the 0.4% UPI MDR on track for October 15, and the Sabarmati LNG train and Kandla e-methanol plant carried the green-fuel push.
Policy Pulse — Ministries & Regulators — 26 Aug 2026
RBI MPC holds repo at 5.25% with GDP raised to 6.7%; Piyush Goyal to visit US for G20 trade meet and USTR talks
Policy Pulse — Ministries & Regulators — 11 Aug 2026
Crude near 90 clouds Sensex (-0.49%) but pharma/IT/refineries shine (Gland +9.6% on Q1 beat, CPCL +14.9%); 'IPOgust' 11 mainboard IPOs raise 21272 cr, lifting BSE/brokers; Shiprocket IPO opens Aug 12
Policy Pulse — Global — 31 Jul 2026
US pharma Section 232 tariffs live (branded protected, generics exempt). India Samudra Manthan energy-security capex (ONGC, OIL). Markets stabilize post-Fed.
Policy Pulse — Ministries & Regulators — 31 Jul 2026
India-US pharma deal exempts Indian generics from Section 232 (BUY SUNPHARMA, DRREDDY, CIPLA). SEBI Stock Brokers Regulations 2026. Nifty Pharma +0.7%.
Policy Pulse — Global Spillover — 24 Jul 2026
Strait of Hormuz crisis at peak — 13th night of US strikes, Iran rejects ceasefire, oil above 00. Generic drug tariff timeline begins Aug 1. Section 122 expiry relief for importers. Stock impact: BUY oil/gas/defence/renewables, SELL airlines/refiners/generic pharma.
Policy Pulse — Modi/Govt — 24 Jul 2026
Cabinet approves ₹3,030 cr BHAVYA Rasayan chemical parks scheme + ₹1,264 cr rail project. India secures lower 10% US tariff under Section 301. Stock impact: BUY chemicals/infra/pharma, SELL steel (US export).
Policy Pulse — Global Spillover — 23 Jul 2026
INFY Q1: +12% PAT, guidance trimmed, ADR -4.85%. INDIGO: ₹238cr net loss on fuel costs (85% rise). CIPLA: -39% PAT. Hormuz: 12th night, Brent near 8. IOC/MRPL halt Iraq loadings. Section 122 expiry tomorrow benefits Indian IT/Textiles. ONGC gains, refiners bleed.
Policy Pulse — Modi / India — 22 Jul 2026
Nifty below 24,000 on Brent 5, IOCs halt Iraq oil loadings due to Hormuz (ONGC gains, IOC/BPCL/HPCL pressured). Trump generic drug tariff crushes Sun Pharma, Lupin, Cipla. Nestlé, Bajaj Auto shine on stellar Q1. Bandhan Bank -19% on RoA cut.
Policy Pulse — Global — 17 Jul 2026
Strait of Hormuz escalation: buy XOM, CVX, OXY, EOG; sell DAL, UAL, AAL, CCL, RCL. Section 301 deadline Jul 20: buy WMT, TGT, COST if Section 122 lapses; sell TCS, INFY, WIPRO, SUNPHARMA if 12.5% tariff hits.
Policy Pulse — Global — 15 Jul 2026
EU-US deal (15% ceiling) in effect, Section 301 deadline July 20, Section 122 expires July 24, USMCA enters annual review — TSLA, TCS, SUNPHARMA positioned across multi-tier tariff shifts.
Policy Pulse — Global — 14 Jul 2026
Global cross-currents: Iran blockade drives oil stocks (XOM, ONGC) higher while hitting airlines (DAL, UAL); US-India trade talks progress; Indian defence exports surge 62% to record (HAL, BEL, SOLARINDS).
Policy Pulse — Ministries — 13 Jul 2026
USTR proposes 12.5% forced labor tariffs on 44 countries including India — textiles hit hardest (WELSPUN, TRIDENT). June retail inflation rises to 4.38%, breaches RBI target. SEBI tightens employee conduct rules (governance only).
Policy Pulse — Modi — 13 Jul 2026
India rejects rushed US trade deal — demands tariff edge over China. Risk of steeper tariffs later this month. IT (TCS, INFY) and textiles (WELSPUN, TRIDENT) exposed. HAL receives 7th GE engine — Tejas Mk1A programme gains momentum.
Policy Pulse — Global Trade — 06 Jul 2026
USTR forced labor tariff hearings Jul 7-9 propose 12.5% duty on 60 economies including India; US pharma tariffs (100% on patented) exclude generics — Neutral for Indian API exporters; USMCA not renewed; Brazil tariff deadline Jul 15. Stocks: SUNPHARMA, DRREDDY, DIVIS, TCS, INFY, TATASTEEL, WELSPUN, RAYMOND.
Policy Pulse — Ministries & Regulators — 06 Jul 2026
India-UK CETA effective Jul 15 — CFOs expanding capacity for textile, auto components, gems & jewellery export boom. SEBI reintroduces open market buyback from Aug 1. India exports set to cross $500B in FY27. Stocks: RAYMOND, WELSPUN, INDOCOUNT, CEAT, BHARATFORG, TITAN, PCJEWELLER.
Policy Pulse — Global Spillover — 03 Jul 2026
USTR proposes 12.5% Section 301 tariffs on India over forced labor findings — hearings Jul 7. Major risk for Indian pharma (Sun Pharma, Dr Reddy's, Cipla, Aurobindo), textiles (Welspun, Trident), and IT (TCS, Infosys).